Key Highlights
- Net loss was USD 7.73 million, compared with USD 7.34 million.
- Loss per share was USD 0.53, compared with USD 1.35.
- Operating loss was USD 7.49 million, compared with USD 6.00 million.
- Cash was USD 23.19 million at September 30, 2026.
Cingulate (NASDAQ:CING) reported a net loss of USD 7.73 million for the third quarter of 2026, compared with USD 7.34 million in the prior-year quarter. Loss per share was USD 0.53, compared with USD 1.35.
For the nine months ended September 30, 2026, the net loss was USD 22.93 million, compared with USD 16.18 million, and loss per share was USD 1.83, compared with USD 3.60.
Research and Administrative Expenses
Research and development expenses were USD 2.91 million, compared with USD 2.85 million, and selling, general and administrative expenses were USD 4.58 million, compared with USD 3.15 million. Operating loss was USD 7.49 million, compared with USD 6.00 million.
The filing reports that drug Manufacturing costs within Research and Development were USD 2.25 million, compared with USD 913 thousand, and pre-commercialization costs within selling, general and administrative expenses were USD 2.00 million, compared with USD 539 thousand.
The change in Fair Value of derivative was a loss of USD 69 thousand, compared with a loss of USD 772 thousand.
Nine-Month Operating Results
For the nine months, research and development expenses were USD 6.58 million, compared with USD 7.77 million, and selling, general and administrative expenses were USD 14.25 million, compared with USD 6.58 million. Operating loss was USD 20.83 million, compared with USD 14.35 million.
Drug manufacturing costs for the nine months were USD 4.33 million, compared with USD 2.40 million, and pre-commercialization costs were USD 7.22 million, compared with USD 650 thousand.
Balance Sheet, Liquidity and Regulatory Update
Cash was USD 23.19 million at September 30, 2026, compared with USD 10.95 million at the prior Balance Sheet date. Total Assets were USD 28.15 million, compared with USD 15.07 million, and total liabilities were USD 7.38 million, compared with USD 12.56 million. Shares outstanding were 14,761,701, compared with 7,250,299.
The company is developing two proprietary stimulant medications for attention Deficit hyperactivity disorder, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The filing states that CTx-1301 is in late-stage development and that the company plans to initiate the clinical plan for CTx-1302 pending additional Capital resources.
The filing states that the new drug application for CTx-1301 was accepted in early October 2025 with a Prescription Drug User Fee Act target action date of May 31, 2026. On June 2, 2026, the company announced that the FDA issued a Complete Response Letter for the application, which identified specific requests for additional Chemistry, Manufacturing and Controls information.
The filing also states that conditions described in its liquidity note result in substantial doubt about the company's ability to continue as a Going Concern within one year after the date that the financial statements are issued.
For the nine months, the net loss was USD 22.93 million and loss per share was USD 1.83. The filing reports total liabilities of USD 7.38 million at September 30, 2026.
Cingulate Q3 2026 Earnings: Key Takeaways
Cingulate reported a third quarter 2026 net loss of USD 7.73 million and a loss per share of USD 0.53. Cash was USD 23.19 million at September 30, 2026.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...